Get informed when a big investor buys or sells
+ FollowOvervalued by 153.1% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $3.33 Million |
|---|---|
| Enterprise Value | $4.10 Million |
| Earnings per Share | $0 |
| Beta | -0.13 |
| Outstanding Shares | 82,164,642 |
| P/E Ratio | -508.23 |
|---|---|
| PEG | 509.88 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -14.95 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.71 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Oncology Pharma Inc. is a pharmaceutical firm specializing in oncology, dedicated to the development, manufacturing, and commercialization of therapeutic agents. The company has a collaborative and licensing agreement with Kalos Therapeu...